MedTrace Logo

To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo

NCT00761540 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2017-01-26

No results posted yet for this study

Summary

This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood concentration of liraglutide (pharmacokinetics) as well as the effects on glucose and insulin (pharmacodynamics) after 21 days of daily subcutaneous injections (injected under the skin) of liraglutide or placebo. In addition, the safety and tolerability of liraglutide will be observed.

Conditions

Interventions

DRUG

liraglutide

Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)

DRUG

placebo

Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)

DRUG

liraglutide

Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)

DRUG

placebo

Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)

DRUG

liraglutide

Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)

DRUG

placebo

Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00761540 on ClinicalTrials.gov